期刊文献+

RPL8基因修饰的树突状细胞对胶质瘤的免疫治疗作用 被引量:3

Anti-glioma Effect of Dendritic Cells Modified by RPL8 Gene
下载PDF
导出
摘要 目的探讨RPL8基因修饰的树突状细胞(DC)对胶质瘤生长的抑制作用。方法通过重组腺病毒将RPL8基因导入树突状细胞,荧光显微镜观察细胞内绿色荧光蛋白的表达,RT-PCR分析细胞内RPL8m RNA表达,RPL8基因修饰的DC与T细胞混合培养,MTT法检测活化T细胞对胶质瘤细胞的杀伤效应。DC注入荷瘤小鼠体内,观察肿瘤体积变化及小鼠生存时间。结果重组病毒转染DC后,细胞内可见绿色荧光,RT-PCR分析细胞内有RPL8m RNA表达;Ad-RPL8组、Ad组及PBS组激活T细胞对GL261细胞的杀伤率分别为78%、49%和43%,Ad-RPL8组较Ad组及PBS组明显增高(P<0.05),RPL8基因修饰的DC注入小鼠后,与Ad组及PBS组比,小鼠生存期明显延长(P<0.05),肿瘤体积变小(P<0.05),肿瘤细胞坏死增多。结论 RPL8基因修饰的DC对胶质瘤具有生长抑制作用,为胶质瘤免疫治疗开辟新途径。 Objective To investigate the anti-glioma effect of dendritic cells(DC) modified by RPL8 gene. Methods DC were infected with the recombinant adenovirus Ad-RPL8. Green fluorescent protein was detected by fluorescence microscopy. Expression of RPL8 m RNA in DC was analyzed by RT-PCR. After the treatment with DC modified by RPL8 gene, the suppression of T cells on GL261 glioma cells was detected by MTT assay. The life span of mice and the pathology morphology of the tumor were analyzed after the mice were injected with DC. Results After infection with Ad-RPL8, green fluorescent and RPL8 m RNA expression were showed. T cells inhibited the growth of GL261 cells after stimulated by DC modified by RPL8 gene. The inhibition rate of T cells on GL261 cells were 78%, 49% and 43% in Ad-RPL8, Ad and PBS group, respectively. The inhibition rate was higer in Ad-RPL8 group than that in Ad and PBS group(P<0.05). The life span of Ad-RPL8 group was significantly prolonged and tumor volume was decreased, compared with Ad and PBS group(P<0.05). Conclusion The DC modified by RPL8 gene could activate T cells to suppress the growth of glioma, which could provide a new method for immunological therapy on glioma.
出处 《肿瘤防治研究》 CAS CSCD 北大核心 2015年第1期19-22,共4页 Cancer Research on Prevention and Treatment
基金 贵州省科学技术基金(黔科合丁字20082198) 遵义市科技计划基金(遵义市科合社字201473)
关键词 胶质瘤 树突状细胞 RPL8 免疫治疗 Glioma Dendritic cells RPL8 Immunotherapy
  • 相关文献

参考文献9

  • 1张晓娟,董坚,吴振林,洪敏,邢海霞.HSP70多肽复合物修饰DCs疫苗抗胰腺癌荷瘤小鼠的实验研究[J].中国免疫学杂志,2009,25(9):792-796. 被引量:12
  • 2Jurjen Tel,Simone P. Sittig,Rebecca A. M. Blom,Luis J. Cruz,Gerty Schreibelt,Carl G. Figdor,I. Jolanda M. de Vries.Targeting Uptake Receptors on Human Plasmacytoid Dendritic Cells Triggers Antigen Cross-Presentation and Robust Type I IFN Secretion[J]. The Journal of Immunology . 2013 (10)
  • 3Felizardo T C,Wang J C M,McGray R A J,Evelegh C,Spaner D E,Fowler D H,Bramson J L,Medin J A.Differential immune responses mediated by adenovirus- and lentivirus-transduced DCs in a HER-2/neu overexpressing tumor model. Gene Therapy . 2011
  • 4Wallet Mark A,Sen Pradip,Tisch Roland.Immunoregulation of dendritic cells. Clinical medicine & research . 2005
  • 5Terando A,Roessler B,Mule J J.Chemokine gene modification of human dendritic cell-based tumor vaccines using a recombinant adenoviral vector. Cancer Gene Therapy . 2004
  • 6Swoboda Rolf K,Somasundaram Rajasekharan,Caputo Laura,Ochoa Elizabeth M,Gimotty Phyllis A,Marincola Francesco M,Van Belle Patricia,Barth Stephen,Elder David,Guerry DuPont,Czerniecki Brian,Schuchter Lynn,Vonderheide Robert H,Herlyn Dorothee.Shared MHC class II-dependent melanoma ribosomal protein L8 identified by phage display. Cancer Research . 2007
  • 7SON C H,BAE J H,SHIN D Y,et al.Ctla-4 blockade enhances antitumor immunity of intratumoral injection of immature dendritic cells into irradiated tumor in a mouse colon cancer model. Journal of Immunotherapy . 2014
  • 8Chen J,Guo XZ,Li HY,et al.Generation of CTL responses against pancreatic cancer in vitro using dendritic cells cotransfected with MUC4and survivin RNA. Vaccine . 2013
  • 9Lauterbach H,Patzold J,Kassub R,et al.Genetic adjuvantation of recombinant MVA with CD40L potentiates CD8 T cell mediated immunity. Front Immunol . 2013

二级参考文献12

  • 1董驹,张树波,马立人,王国臣,陈志全,郑毛根.小鼠肺腺癌热休克蛋白70-抗原肽复合物的纯化[J].中国煤炭工业医学杂志,2004,7(11):1109-1111. 被引量:2
  • 2Srivastava P K, Menoret A, Basu Set al. Heat shock protein come of age: primitive functions acquire new roles in an adaptive world[J]. Immunity, 1998;8(6) :657-665.
  • 3胡美英 梁明达 贾伟 et al.小鼠可移植性胰腺腺泡细胞癌株(MPC-83)的建立及其特性研究.昆明医学院学报,1994,6(2):2-7.
  • 4Peng P, Menoret A, Srivastava P K. Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography[J]. J Immunol Methods, 1997;204( 1 ) : 13-21.
  • 5Udono H, Srivastava P K. Heat shock protein 70 associated peptides elicit specific cancer immunity[ J ]. J Exp Med, 1993 ; 178(4) : 1391-1396.
  • 6Massa C, Melani C, Colombo M P. Chaperon and adjuvant activity of hsp70: different natural killer requirement for crosspriming of chaperoned and bystander antigens[ J]. Cancer Res, 2005 ; 65 : 7942-7949.
  • 7Schmitt E, Gehrmann M, Brunet Met al. Intracellular and extracellular functions of heat shock protein : repercussions in cancer therapy [ J ]. J Leukoc Biol, 2007 ; 81 : 15-27.
  • 8Zeng Y, Graner M W, Katsanis E. Chaperone-rich cell lysates, immune activation and tumor vaccination [ J ]. Cancer Immunol Immunother, 2006; 55 : 329-338.
  • 9Kammerer R, Sober D, Riedl Pet al. Noncovalent association with stress protein facilitates cross-priming of CD8^+ T cells to tumor cell antigens by dendritic cells[ J]. J Immunology, 2002 ; 168 : 108-117.
  • 10Hashemi S M, Hass Z M, Soudi Set al. Evaluation of anti-tumor effects of tumor cell lysate enriched by HSP-70 against fibrosarcoma tumor in BALB/c mice[ J ]. Int Immunophamarcol, 2007 ;7 : 920-927.

共引文献12

同被引文献21

  • 1孙彦辉,张亚卓,王忠诚,孙梅珍,赵东海.MGMT在脑胶质瘤组织中的表达及其与患者生存期的关系[J].癌症,2004,23(9):1052-1055. 被引量:36
  • 2Wang CW, Wang CK, Chang YJ, et al. Preclinical evalua- tion on the tumor suppression efficiency and combination drug. effects of fermented wheat germ extract in human ovarian carci- noma ceils [ J ]. Evid Based Complement Ahernat Med: eCAM, 2015, 2015: 570-785.
  • 3Song X, Airan RD, Arifin DR, et al. Label-free in vivo mo- lecular imaging of underglycosylated mucin- 1 expression in tumour celts [J]. Nat Commun, 2015, 6: 6719.
  • 4Kanda Y. Fertility preservation in patients with hematological malignancies [J]. GanTo Kagaku Ryoho, 2015, 42 (3): 261-266.
  • 5Skodras A, Marcelli G. Computer-generated ovaries to assist follicle counting experiments [J]. PloS One, 2015, 10 (3) : e0120242.
  • 6Fekonja A, Cretnik A, Zerdoner D, et al. Hypodontia phe- notype in patients with epithelial ovarian cancer [ J ]. Radiol Oncol, 2015, 49 (1): 65-70.
  • 7Gsiorowska E, Michalak M. Clinical application of HE4 and CA125 in ovarian cancer type I and type II detection and differential diagnosis [J]. Ginekol Pol, 2015, 86 (2): 88 -93.
  • 8Chester C, Dorigo O, Berek JS, et al. Immunotherapeutic approaches to ovarian cancer treatment [ J ]. J Immunother Cancer, 2015, 3 (1): 7.
  • 9Tkalia IG, Vorobyova LI, Grabovoy AN, et al. The antitu- mor efficacy of cisplatin in combination with triptorelin and ex- emestane therapy for an ovarian cancer ascites model in Wistar rats [J]. Exp Oneol, 2015, 37 (1): 30-35.
  • 10Shepherd SM, de Jonge M. P1.03 analysis of biomarkers and PK modeling of ABT-767 in patients with BRCA1/BRCA2- mutated tumors or high grade serous ovarian cancer [ J ]. Ann Oncol, 2015, 26 (2): 16-17.

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部